Cellumed
Cellumed is a Korean biotech and medical device company developing bone graft materials (Rafugen DBM, Bio BMP2), acellular dermal matrix products (CELLUDERM), mRNA production enzymes (CLnZyme), and AI-integrated surgical robotics for hospitals, dental clinics, and pharmaceutical companies.
- Company typePublic
- Founded2005
- HeadquartersGeumgok, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellumed does
Cellumed is a Korean biotechnology and medical device company headquartered in Seoul, South Korea, that develops and manufactures musculoskeletal medical devices, tissue-engineered products, and biopharmaceutical manufacturing inputs. Its core product portfolio includes bone graft materials (Bio BMP2 recombinant human bone morphogenetic protein-2 coated on demineralized bone matrix, and Rafugen DBM demineralized bone matrix with US FDA approval since 2018), acellular dermal matrix products under the CELLUDERM brand (HD Implant, FILL, GEN, ULTRA, POWER variants) for breast reconstruction, plastic surgery, urology, and orthopedic applications, mRNA production enzymes under the CLnZyme brand (T7 RNA polymerase, DNase I, Pyrophosphatase), patient-specific surgical instruments (PSI) and AI-integrated surgical robot software, and recombinant growth factors (TGF-β1, FGF7) for cosmetic and medical applications.
Cellumed's business model is primarily one-time product sales (hardware) to hospitals, dental clinics, and pharmaceutical companies through direct enterprise sales and channel partnerships. The company employs an enterprise field sales motion targeting major Korean university hospitals (securing hospital codes at 14 major institutions for CELLUDERM breast reconstruction products) and uses distribution partners for specific product lines including Renew Medical (minimum 70 billion KRW annual dental powder supply agreement), Ezen Implant (ODM), and Ostem Implant (OEM for China distribution). The company also serves pharmaceutical companies with mRNA enzymes, including a partnership with Ijin for mRNA vaccine development. Cellumed holds multiple regulatory approvals including US FDA (Rafugen DBM, 2018), Taiwan FDA, Thailand FDA for BMP2, and ISO 13485 recertification (2025), enabling international market access.
Cellumed's consolidated operations include subsidiary Environment E&J (Hwangyeong Engineering), a construction company specializing in mechanical and fire protection equipment installation that contributes approximately 1 trillion KRW in annual revenue to consolidated financials. The company is listed on KOSDAQ (ticker 049180) and faces significant going concern issues following a 2025 fiscal year audit opinion rejection (issued April 2026) over subsidiary loan documentation and US lawsuit settlement liability concerns, triggering stock trading suspension and Korea Exchange delisting review. The company's largest shareholder changed in early 2026 through a 170 billion KRW rights offering to TD Landmark Union 1, which has signaled intent for management normalization and non-core asset divestiture.
Cellumed firmographics
Firmographics- Name
- Cellumed
- Legal name
- (주)셀루메드
- Website
- https://cellumed.co.kr
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cellumed is a Korean biotech and medical device company developing bone graft materials (Rafugen DBM, Bio BMP2), acellular dermal matrix products (CELLUDERM), mRNA production enzymes (CLnZyme), and AI-integrated surgical robotics for hospitals, dental clinics, and pharmaceutical companies.
- Ownership category
- akta.pro rank
Cellumed industry classification
Industry- Product category
- Orthopedic and Tissue Engineering Medical Devices
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Dental Equipment and Supplies Manufacturing (339114)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industries
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Cellumed is headquartered
LocationHeadquarters
- HQ city
- Geumgok
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Cellumed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Medical Devices (Bone Graft Materials): Sale of bone graft materials including Rafugen DBM, Bio BMP2, and dental bone graft products. These are one-time product sales for surgical procedures in orthopedics and dentistry.
- Tissue Bank Products: Human tissue-based products including acellular dermal matrix (CELLUDERM series) for reconstructive surgeries. One-time product sales with recurring demand from surgical procedures.
- mRNA Production Enzymes: Supply of GMP-grade mRNA production enzymes (CLnZyme brand) to pharmaceutical companies for mRNA vaccine and therapeutic development. Includes sample supply and long-term supply agreements.
- Cosmeceutical Products: Bioactive cosmetic ingredients and products containing growth factors (FGF7, TGF-β1) supplied to parent company Insco Bio and through various distribution channels.
- Construction (Subsidiary Environment E&J): Construction subsidiary revenue from facility and equipment installation projects for large commercial and residential developments. Significant contribution to consolidated revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B institutional pricing for medical facilities |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Cellumed product offering
Product offeringCore offering
Cellumed manufactures and sells bone graft materials (Bio BMP2 recombinant protein, Rafugen DBM demineralized bone matrix), acellular dermal matrix (CELLUDERM) skin graft products for reconstructive surgery, GMP-grade mRNA production enzymes under the CLnZyme brand, recombinant growth factors (TGF-β1, FGF7), and AI-integrated patient-specific surgical robotics for joint replacement. The company sells primarily to hospitals, dental clinics, and pharmaceutical companies in Korea and internationally, with manufacturing subsidiaries for biologics and construction.
Product overview
Cellumed is a biotechnology and medical device company organized into multiple divisions spanning Tissue Bank, Medical Devices, mRNA Enzymes, Cosmeceuticals, and Electric Vehicles. Its core medical device portfolio centers on bone graft materials — including Bio BMP2 (rhBMP2-coated demineralized bone matrix), Rafugen DBM (FDA-approved bone graft), and Dental Powder — along with the CELLUDERM series of acellular dermal matrix (ADM) skin graft products (HD Implant, FILL, GEN, ULTRA, POWER). The company also develops AI-integrated surgical robotics combining PSI (patient-specific instrument) pre-planning with Cueresso's robotic system for joint replacement, and manufactures mRNA synthesis enzymes under the CLnZyme brand. Additional offerings include growth factors (TGF-β1, FGF7) for skincare, the BMG meniscus graft, and wellness products (ODF films). The Tissue Bank division processes human allografts, while the company has diversified into EV battery platforms via BYD partnership.
Differentiator
Problem solved
Functional benefit
Brands
- CELLUDERM: Acellular dermal matrix (ADM) skin graft product line including HD Implant, FILL, GEN, ULTRA, and POWER variants for breast reconstruction and tissue regeneration
- Rafugen DBM
- Bio BMP2
- CLnZyme
- Lapugen
- BMG (Bio Meniscus Graft)
- Viscoil
Products and services
- Bio BMP2 Bone graft material combining demineralized bone matrix from donated human cadaveric bone coated with CHO-cell-derived recombinant human BMP2 (rhBMP2), mixed with sodium carboxymethyl cellulose and collagen gel from porcine skin. Used for alveolar bone defect filling to promote bone regeneration and preservation in orthopedic and dental procedures.
- Rafugen DBM (라퓨젠 DBM) Demineralized bone matrix (DBM) bone graft material FDA-approved in 2018 for bone regeneration, also approved in Taiwan (2021) and Thailand. Uses a proprietary sterilization method (cold treatment before gamma irradiation) that preserves material physical properties while eliminating pathogens. Used for spinal fusion, orthopedic trauma, and bone defect filling.
- Dental Powder (덴탈 파우더) Human allogeneic bone graft material for dental implant procedures. Used to fill bone defects after tooth extraction and for socket preservation, bone ridge augmentation. Supplied to Renew Medical (under Renew Oss brand) and Ostem Implant as OEM, with a minimum 70 billion KRW annual supply contract with Renew Medical.
- CLnZyme (mRNA Production Enzymes) mRNA synthesis enzyme brand producing key enzyme proteins for mRNA vaccine and therapeutic production, including T7 RNA polymerase, DNAse I, and Pyrophosphatase. Developed in partnership with German biotech Artes Biotechnology. 5 types of GMP-grade mRNA production enzymes supplied to pharmaceutical companies including Ijin.
- CELLUDERM HD Implant Acellular dermal matrix (ADM) skin graft product for breast reconstruction, soft tissue reconstruction, and burn treatment. Uses human dermis processed to remove immunogenic cells while preserving collagen and elastin ECM structure. Available in implant form.
- CELLUDERM FILL Injectable acellular dermal matrix (ADM) micropowder formulation mixed with purified water or biopolymer carrier. Available in 3cc and 8cc formats; designed for plastic surgery, breast surgery, orthopedics, and urology applications.
- CELLUDERM GEN / ULTRA / POWER Series Series of ADM-based skin graft products for various clinical indications including plastic surgery, urology, and orthopedics. Each variant (GEN, ULTRA, POWER) is tailored for specific surgical applications, with GEN positioned as next-generation injectable skin graft for therapeutic and cosmetic dual-use.
- Tissue Bank Services (조직 은행) Processes donated human tissues into safe, high-quality allograft materials for transplantation. Develops tissue engineering products. KBB Tissue Bank holds US FDA registration (2007) and Korean MFDS tissue processing authorization (2006). Supplies allograft materials used across Cellumed's bone graft and dermal matrix product lines.
- PSI (Patient-Specific Instrument) + AI Surgical Robot System Patient-specific pre-operative surgical planning and AI-integrated robotic surgery assistance. Combines CT scan-based 3D anatomical reconstruction, biomechanical analysis, and Curexso's Qubeis-Joint robotic surgical system for artificial joint replacement. 4 patents registered in AI surgery design domain. Used at major Korean hospitals including Seoul National University Hospital, Severance Hospital, and Jeju University Hospital with over 700 successful surgeries.
- BMG (Bio Meniscus Graft) Knee meniscus partial replacement graft — Korea's first MFDS-approved product. Clinical sites include Kyunghee Medical Center, Hanyang University Medical Center, and Samsung Seoul Hospital. Used for knee meniscus repair and replacement procedures.
- TGF-β1 / FGF7 Growth Factors Recombinant growth factor proteins developed for skincare and medical applications. TGF-β1 (transforming growth factor beta 1) is DNA-sequence-matched 100% to human skin and used for anti-aging, wound healing, and scar treatment. FGF7 (fibroblast growth factor 7) supports skin cell regeneration. Mass-produced after 10 years of government research.
- Proteoglycan Gwan-jil Kwang-kwang (ODF Health Functional Food) Oral dissolving film (ODF) health functional food containing 527mg of proteoglycan, chondroitin, and glutathione per film. Targets joint health and wellness market with sublingual absorption for high bioavailability.
Quantifiable outcome
- BMP2 production yield improvement target: 5x increase through ATC+ government project
- +2 more outcomes
Companies that use Cellumed
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Cellumed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Cellumed partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major, core and minor.
- Seogang University (서강대)majorJoint development of pancreatic cancer and idiopathic pulmonary fibrosis therapeutics using RNA-LNP technology.
- Cognitive (코넥티브)majorStrategic partnership with Seoul National University Hospital Professor Noh Do-hyun's startup for AI and big data-based 3D joint surgery pre-planning system and 3rd generation surgical robot R&D.
- Renew Medical (리뉴메디칼)majorDental powder supply agreement with minimum 70 billion KRW annually. Cellumed supplies dental bone graft materials for distribution under Renew Medical's brand.
- Gaion (가이온)majorStrategic partnership for AI and big data-based imaging analysis systems. Integration of Gaion's gSmartVision AI technology with Cellumed's PSI and surgical robot software for enhanced preoperative planning.
- Curexso (큐렉소)coreSurgical robot software development partnership. Curexso's Qubeis-Joint robot integrated with Cellumed's fixed-type and mobile-type artificial joints for robotic surgery system. FDA registration target for US market.
- Shenzhen Alpha BiotechnologymajorMOU for mRNA production enzyme supply and joint R&D for China market entry. Shenzhen-based biotech specializing in vaccines and pharmaceuticals.
- Artes Biotechnology (아르떼)coreContract development and technology transfer for mRNA production enzyme development. German biotech company providing process development for GMP-grade enzyme production. 2 types of mRNA production enzymes under joint development.
- Yejin Pharma (이연제약)majorMOU for GMP mass production of 5 types of mRNA production enzymes and joint R&D for mRNA-based vaccines and therapeutics using Cheongju bio facility.
- Apimez (아피메즈) / Pohang UniversitymajorJoint research for cervical cancer HPV antibody diagnostic and vaccine development. Plant-based recombinant protein platform using Professor Hwang In-hwan's green vaccine technology.
- Ijin (아이진)coreMain contract for mRNA-based vaccine and anticancer drug development. Cellumed developing 5 types of mRNA production enzymes for supply to Ijin. Joint development of COVID-19 mRNA vaccine with technology transfer and mass production process development.
- Chungnam Geumsan County (충남 금산군)minorMedical welfare support MOU providing medical examinations and surgeries for economically disadvantaged residents aged 65+ in Geumsan county.
- Major Korean University HospitalscoreClinical research partnerships with Seoul National University Hospital, Severance Hospital, Jeju University Hospital, Myeongji Hospital for PSI knee replacement procedures. Over 700 surgical cases completed.
- Ostem Implant (오스템임플란트)majorDBM dental bone graft products supplied under OEM arrangement. China's leading dental implant company distributing Cellumed products.
- Environment E&J (환경이엔지) - SubsidiarycoreConstruction subsidiary specializing in mechanical and fire protection equipment installation. Major construction company partnerships including 1-tier builders. Revenue contribution to consolidated financials.
- Korea Construction & Environment Research Institute (한국건설생활환경시험연구소)majorT7 RNA polymerase performance evaluation conducted by Korea's largest testing and certification institute for quality validation and certification of mRNA enzyme products.
Scale indicators12 records
Recent moves9 records
Expansion highlights6 records
Cellumed competitors and assessment
Company assessmentDirect peers
- Organogenesis: US regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft). Direct peer to Cellumed's CELLUDERM acellular dermal matrix product line serving similar plastic surgery, wound healing, and reconstructive applications.
- Aldevron: US-based manufacturer of high-quality plasmid DNA, mRNA, and proteins for biotech and pharmaceutical customers. Direct peer to Cellumed's CLnZyme mRNA production enzyme business, serving the same mRNA vaccine and therapeutic developer customer base.
- Medtronic: Global medical device leader whose INFUSE Bone Graft (rhBMP2) product directly competes with Cellumed's Bio BMP2 in the bone graft substitute market. Medtronic is the dominant commercial BMP2 supplier globally and serves as the primary benchmark for Cellumed's BMP2 ambitions.
- MiMedx: US company specializing in placental tissue allografts and regenerative medicine products. Comparable to Cellumed through its focus on allograft tissue processing for wound healing, surgical recovery, and tissue regeneration applications.
- LifeNet Health: Non-profit organ procurement and tissue banking organization providing allograft tissue for orthopedic, spine, and reconstructive surgery. Direct competitor to Cellumed's tissue bank division with similar allograft product offerings for bone regeneration.
- MTF Biologics: Non-profit tissue bank and regenerative medicine organization that processes donated human allograft tissue for surgical use, mirroring Cellumed's KBB Tissue Bank operations. Direct peer in the allograft tissue processing and distribution segment.
- Integra LifeSciences: US medical device company specializing in orthopedic biologics, dural repair, and regenerative tissue products. Comparable to Cellumed through its allograft/demineralized bone matrix portfolio and similar focus on surgical reconstruction applications.
Broad incumbents
- Stryker: Global orthopedic medical device leader offering joint replacement, trauma, and surgical navigation systems. Broad incumbent competitor to Cellumed's orthopedic bone graft and PSI surgical instrument offerings, though Stryker operates at much greater scale across multiple orthopedic segments.
Regional players
- Pharmicell: Korean biotech company specializing in stem cell therapy and regenerative medicine products including cell therapy for cartilage regeneration. Comparable to Cellumed through its Korean market presence and focus on musculoskeletal/cartilage regenerative medicine applications.
- Corestem: Korean biotech company developing stem cell therapies for autoimmune and degenerative diseases including chondrogenic applications. Regional peer to Cellumed in Korean regenerative medicine market with overlapping musculoskeletal and cartilage-focused research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Cellumed social profiles
Digital presenceCellumed compliance and trust
Trust signalCompliance3 records
Cellumed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellumed leadership team
Management profileNumber of profiles
Profiles4 records
Cellumed subsidiaries and ownership
Company hierarchySubsidiaries4 records
Cellumed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellumed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellumed
What does Cellumed do?
Cellumed manufactures and sells bone graft materials (Bio BMP2 recombinant protein, Rafugen DBM demineralized bone matrix), acellular dermal matrix (CELLUDERM) skin graft products for reconstructive surgery, GMP-grade mRNA production enzymes under the CLnZyme brand, recombinant growth factors (TGF-β1, FGF7), and AI-integrated patient-specific surgical robotics for joint replacement. The company sells primarily to hospitals, dental clinics, and pharmaceutical companies in Korea and internationally, with manufacturing subsidiaries for biologics and construction.
Is Cellumed a public or private company?
Cellumed is a public company. It is classified as public and is currently operating.
When was Cellumed founded?
Cellumed was founded in 2005. It employs 51 to 100 people.
Where is Cellumed based?
Cellumed is headquartered in Geumgok, South Korea, in the Asia region.
How does Cellumed make money?
Five revenue lines are on record. Medical Devices (Bone Graft Materials) is the primary driver. The others are tissue Bank Products, mRNA Production Enzymes, cosmeceutical Products and construction (Subsidiary Environment E&J).
Who are Cellumed's main competitors?
Direct peers on record are Organogenesis, Aldevron, Medtronic, MiMedx, LifeNet Health, MTF Biologics and Integra LifeSciences. Stryker is listed as a broad incumbent. Regional players are Pharmicell and Corestem.
Does Cellumed have an API?
No public API is recorded for Cellumed.
What industry is Cellumed in?
Cellumed's product category is Orthopedic and Tissue Engineering Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.